Company Overview - Ventyx Biosciences develops oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases [3] Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating Ventyx for potential violations of federal securities laws due to allegations of misleading business information [1] - On December 2, 2025, Ventyx announced a delay in the Phase 2 trial of VTX2735 for recurrent pericarditis, with topline results now expected in Q1 2026. This delay is attributed to testing a new once-daily formulation and expanding the study into Canada, the EU, and the UK [4] - Following the announcement, Ventyx's stock price dropped by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [4]

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Coupang, Inc. (NYSE: CPNG). Shareholders who purchased shares of CPNG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/coupang-inc-loss-submission-form-2/?id=182867&from=3  CLASS PERIOD: August 6, 2025 to ...

Core Insights - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that additional evidence of effectiveness is required for a favorable benefit-risk assessment [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on the same day [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Klarna Group plc due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding loss reserves following its IPO [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the February 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Klarna [4]. - The complaint alleges that Klarna and its executives materially understated the risk of increased loss reserves shortly after the IPO, which they either knew or should have known [6]. - Investors are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights and options [1][10]. Group 2: Financial Performance and Market Reaction - Klarna reported a net loss of $95 million in its third quarter, while setting aside $235 million for loan loss provisions, exceeding analyst estimates of $215.8 million [7]. - Provisions for loan losses represented 0.72% of gross merchandise volume, an increase from 0.44% a year ago [7]. - Following the earnings report, Klarna's stock experienced a decline of 9.3% on November 18, 2025 [7].

Core Viewpoint - Jefferies Financial Group Inc. and Point Bonita Capital are under investigation for potential violations of federal securities laws following a probe by the SEC related to their exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital is its trade finance arm [2]. - Both firms were closely associated with First Brands Group, an auto parts supplier that declared bankruptcy with $12 billion in debt [2][4]. Group 2: Financial Exposure - On October 8, 2025, Jefferies and Point Bonita disclosed approximately $715 million in exposure to First Brands' receivables, accounting for about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: SEC Investigation Details - The SEC is investigating whether Jefferies provided adequate information to investors regarding their exposure to the auto business, particularly in light of First Brands' bankruptcy [4]. - The investigation also includes scrutiny of internal controls and potential conflicts of interest within Jefferies and Point Bonita [4]. Group 4: Legal Implications - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors regarding their exposure to First Brands [5].

Core Viewpoint - The complaint against Blue Owl alleges violations of federal securities laws due to misleading statements and undisclosed liquidity issues, particularly related to BDC redemptions and the impact of a merger on investor redemptions [2][3][4]. Group 1: Allegations and Issues - Blue Owl is accused of experiencing significant pressure on its asset base from BDC redemptions, leading to undisclosed liquidity issues [2]. - The company is likely to limit or halt redemptions of certain BDCs, which contradicts previous positive statements made by the defendants regarding the company's business and prospects [2]. - A report indicates that Blue Owl has blocked redemptions in one of its private credit funds due to a merger, potentially resulting in large losses for investors [3]. Group 2: Financial Impact - Following the announcement of the merger, investors in Blue Owl Capital Corporation II will lose the ability to redeem cash at the fund's Net Asset Value (NAV), with shares trading approximately 20% below NAV [4]. - On November 17, 2025, Blue Owl's stock price fell by $0.85, or 5.8%, closing at $13.77 per share, indicating a negative market reaction and potential injury to investors [4].

Core Viewpoint - The complaint alleges that F5 and its executives violated federal securities laws by making misleading statements regarding the company's security capabilities, particularly in light of a significant security breach affecting key offerings [2][3]. Financial Impact - On October 27, 2025, F5 announced fourth quarter fiscal year 2025 results, revealing growth expectations for fiscal 2026 were significantly below market due to the security breach, leading to expected reductions in sales and renewals, elongated sales cycles, terminated projections, and increased remediation expenses [3]. - Following the announcement, F5's stock price dropped from $290.41 per share on October 27, 2025, to $258.76 per share on October 28, 2025, marking a decline of 10.9% within two days [4]. Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the putative class [5]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [5]. Whistleblower Encouragement - The law firm Faruqi & Faruqi encourages individuals with information regarding F5's conduct, including whistleblowers and former employees, to come forward [6].

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm Point Bonita Capital are under investigation for potential violations of federal securities laws following a probe by the SEC related to their exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital is its trade finance division [2]. - Both firms were significant partners of First Brands Group, an auto parts supplier that declared bankruptcy with $12 billion in debt [2][4]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, accounting for about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: SEC Investigation Details - The SEC is investigating whether Jefferies provided adequate information to investors regarding their exposure to the auto business, particularly in light of First Brands' bankruptcy [4]. - The investigation also includes scrutiny of internal controls and potential conflicts of interest within Jefferies and Point Bonita [4]. Group 4: Legal Implications - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors concerning their exposure to First Brands and the SEC probe [5].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited for alleged violations of securities laws, specifically related to misleading statements made by the company during a specified class period [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from October 21, 2025, to November 12, 2025 [2]. - The lawsuit claims that Charming Medical made false and misleading statements that led to the suspension of trading of its shares by the SEC due to an investigation into a scheme to artificially inflate the company's share price [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although being appointed as lead plaintiff is not necessary to participate in any recovery [2]. - The deadline for participation in the lawsuit is set for February 17, 2026 [2]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, indicating a strong reputation in the field [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Blue Owl Capital Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by February 2, 2026 [1][3]. Group 1: Allegations Against Blue Owl Capital - The complaint alleges that Blue Owl and its executives made false or misleading statements and failed to disclose significant issues, including pressure on its asset base from BDC redemptions [3]. - It is claimed that Blue Owl is facing undisclosed liquidity issues and may limit or halt redemptions of certain BDCs, which misled investors regarding the company's business and prospects [3]. - The Financial Times reported that Blue Owl has blocked redemptions in one of its private credit funds due to a merger, potentially leading to large losses for investors [4]. Group 2: Impact on Investors - Following the news of the merger, investors in Blue Owl Capital Corporation II will permanently lose the ability to redeem cash at the fund's Net Asset Value (NAV), instead trading shares for publicly traded Blue Owl shares, which are currently about 20% under NAV [5]. - On November 17, 2025, Blue Owl's stock price fell by $0.85, or 5.8%, closing at $13.77 per share, indicating a negative impact on investors [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who can adequately represent the class, with options for other members to participate or remain absent [6]. - Faruqi & Faruqi encourages individuals with information regarding Blue Owl's conduct to come forward, including whistleblowers and former employees [7].